| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| Other Sizes |
| Targets |
Tripalmitin does not have a defined biological target as it is not a pharmaceutical agent. It is a triglyceride that serves as a storage form of fatty acids and is metabolized by lipases to release palmitic acid for energy production. It is used as a reference standard and in lipid research.
|
|---|---|
| ln Vitro |
Tripalmitin is not a bioactive compound with defined pharmacological activity. It is used as a reference standard in lipid analysis and as a substrate for lipase activity assays. The compound's in vitro activity is related to its role as a lipid substrate rather than as a drug with receptor-mediated effects.
|
| ln Vivo |
Tripalmitin is not used as a therapeutic agent and does not have defined pharmacological activity. It is a component of natural fats and oils and is metabolized to provide energy. The compound has been studied for its effects on morphologies and tensile properties of polymers.
|
| Enzyme Assay |
In vitro assays for Tripalmitin typically involve measuring lipase activity using Tripalmitin as a substrate. The compound is incubated with lipase, and the release of free fatty acids is measured using titration or colorimetric methods. Enzyme kinetics parameters such as Km and Vmax can be determined. Tripalmitin is also used as a reference standard in chromatographic analysis of lipids.
|
| Cell Assay |
Cell-based assays are not typically performed with Tripalmitin as it is not a bioactive compound. The compound is used as a lipid standard and as a substrate in enzyme activity assays. It is not intended for use in cellular assays or as a therapeutic agent.
|
| Animal Protocol |
In vivo animal studies are not applicable for Tripalmitin as it is not a therapeutic agent. The compound is a natural triglyceride found in fats and oils. It is metabolized normally as part of dietary fat digestion and absorption. It is not administered as a drug in standard pharmacological studies.
|
| ADME/Pharmacokinetics |
Tripalmitin has a molecular weight of 807.3 and a molecular formula of C51H98O6. It appears as a white, crystalline powder. The compound has a melting point of 66-68°C and a boiling point of 310-320°C. It is soluble in ether and chloroform but insoluble in water. It should be stored at room temperature in a cool and dark place (<15°C).
|
| Toxicity/Toxicokinetics |
Tripalmitin is generally considered safe and is a component of natural fats and oils. It is not associated with significant toxicity. The intraperitoneal lethal dose in mice is >500 mg/kg. The compound is safe in the present practices of use and concentration. It may be toxic to aquatic life with long-lasting effects (H411).
|
| Additional Infomation |
Tripalmitoylglycerol is a triglyceride obtained by acylation of the three hydroxyl groups of glycerol with palmitic acid (hexadecanoic acid). Functionally, it is related to hexadecanoic acid. Tripalmitoylglycerol has been reported to exist in common wheat (Triticum aestivum), whorled pine (Sciadopitys verticillata), and other organisms with relevant data. TG (16:0/16:0/16:0) is a metabolite found or produced in Saccharomyces cerevisiae.
Tripalmitin is a triglyceride composed of three palmitic acid molecules esterified to a glycerol backbone. It is commonly found in natural fats and oils and is used as a reference standard in lipid analysis. The compound is also known as glycerol tripalmitate and glyceryl tripalmitate. It is not a therapeutic agent and is available for research and analytical purposes. |
| Molecular Formula |
C51H98O6
|
|---|---|
| Molecular Weight |
807.32022
|
| Exact Mass |
806.736
|
| CAS # |
555-44-2
|
| Related CAS # |
Propane-1,2,3-triyl tripalmitate-d31;241157-04-0;Propane-1,2,3-triyl tripalmitate-13C3;168294-57-3;Propane-1,2,3-triyl tripalmitate-13C;Propane-1,2,3-triyl tripalmitate-d5;60763-98-6;Propane-1,2,3-triyl tripalmitate-13C3-1;201996-42-1;Propane-1,2,3-triyl tripalmitate-13C2;339080-65-8;Propane-1,2,3-triyl tripalmitate-d98;1219803-85-6;Propane-1,2,3-triyl tripalmitate-d27;1219804-91-7;Propane-1,2,3-triyl tripalmitate-d9-1;285979-78-4;Propane-1,2,3-triyl tripalmitate-d6;241157-06-2
|
| PubChem CID |
11147
|
| Appearance |
White to off-white solid powder
|
| Density |
0.9±0.1 g/cm3
|
| Boiling Point |
759.8±27.0 °C at 760 mmHg
|
| Melting Point |
66-68 °C
|
| Flash Point |
286.1±23.8 °C
|
| Vapour Pressure |
0.0±2.6 mmHg at 25°C
|
| Index of Refraction |
1.465
|
| LogP |
22.08
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
50
|
| Heavy Atom Count |
57
|
| Complexity |
798
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
PVNIQBQSYATKKL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C51H98O6/c1-4-7-10-13-16-19-22-25-28-31-34-37-40-43-49(52)55-46-48(57-51(54)45-42-39-36-33-30-27-24-21-18-15-12-9-6-3)47-56-50(53)44-41-38-35-32-29-26-23-20-17-14-11-8-5-2/h48H,4-47H2,1-3H3
|
| Chemical Name |
2,3-di(hexadecanoyloxy)propyl hexadecanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :< 1 mg/mL
Ethanol :< 1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2387 mL | 6.1933 mL | 12.3867 mL | |
| 5 mM | 0.2477 mL | 1.2387 mL | 2.4773 mL | |
| 10 mM | 0.1239 mL | 0.6193 mL | 1.2387 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT02980029 | Terminated | Drug: TVB-2640 Other: Placebo |
Colon Cancer | Mark Evers | 2017-10-06 | Phase 1 |
| NCT01494909 | Unknown status | Dietary Supplement: Ensure plus | Cystic Fibrosis | Texas A&M University | 2011-01 | Not Applicable |
| NCT03002168 | Completed | Dietary Supplement: Alpha-cyclodextrin Dietary Supplement: Placebo Radiation: Triolein radiolabeled with 100 microcuries of 3^Hydrogen Radiation: Tripalmitin radiolabeled with 20 microcuries of 14^Carbon |
Healthy Participants | Mayo Clinic | 2017-01-20 | Not Applicable |
| NCT03324191 | Completed | Dietary Supplement: Placebo Dietary Supplement: Tea beverage Dietary Supplement: Tea extract (medium concentration) |
Diabetes Lipid Metabolism |
University of Bath | 2017-10-10 | Not Applicable |
| NCT02999620 | Completed | Dietary Supplement: Alpha-cyclodextrin
Dietary Supplement: Placebo |
Healthy Volunteers | SFI Research | 2017-01 | Not Applicable |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
